atara biotherapeutics, inc. atara biotherapeutics. Atara Biotherapeutics, Inc. has 185 total employees across all of its locations. Asset Turnover measures how quickly a company turns over its asset through sales. View Company $ 18.61 ... Atara Biotherapeutics Cash Flow. View ATRA financial statements in full. Prior to joining Atara, he served as the Chief Medical Officer at Gossamer Bio, overseeing global development, regulatory, and quality activities for the company, and advancing therapeutics in the disease areas of immunology, inflammation, and oncology. Dr. Dupont is committed to bringing transformative therapies to patients. Atara Bio Employee Directory. ATARA BIOTHERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ATARA BIOTHERAPEUTICS, INC. Stock | ATRA | US0465131078 Atara Biotherapeutics earns the No. Atara Biotherapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Get the detailed quarterly/annual income statement for Atara Biotherapeutics, Inc. (ATRA). Atara Biotherapeutics Inc operates in the United States healthcare sector. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Atara Biotherapeutics market cap is $1.7 b. Atara Biotherapeutics, Inc. Common Stock (ATRA) Revenue EPS : Back to ATRA Overview ©2020, EDGAR®Online, a division of Donnelley Financial … This table compares SpringWorks Therapeutics and Atara Biotherapeutics' top-line revenue, earnings per share (EPS) and valuation. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate … This is the Atara Biotherapeutics company profile. Atara Biotherapeutics, Inc. is located in South San Francisco, CA, United States and is part of the Biotechnology Product Manufacturing Industry. Annual. Vera Bradley has generated $0.63 earnings per share over the last year and currently has a price-to-earnings ratio of 50.9. Do the numbers hold clues to … Estimated Average Forecasted Atara Biotherapeutics Price: 13.46. Privacy Policy; Sitemap Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara Biotherapeutics General Information Description. Find out the revenue, expenses and profit or loss over the last fiscal year. Comparatively, Atara Biotherapeutics has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Conference Call and Webcast Today at 4:30 p.m. EDT. Its revenue for the quarter was up 57.4% compared to the same quarter last year. The Income Statement (earnings report) for Atara Biotherapeutics Inc. Find the company's financial performance, revenue, and more. The company earned $139.38 million during the quarter, compared to the consensus estimate of $140.55 million. * atara biotherapeutics (atra)- cash, cash equivalents and short-term investments as of march 31 totaled $435.2 million, as compared to $500.7 million as of dec 31. Atara Biotherapeutics revenue from 2013 to 2020. The top 10 competitors average 3.9B. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The key questions answered in this report: ... Revenue (Value), Price Trend by Type. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel … Atara Bio corporate office is located in 611 Gateway Blvd, Suite 900, South San Francisco, California, United States and has 454 employees. Atara Biotherapeutics earns the No. Its revenue … All content is posted anonymously by employees working at Atara Biotherapeutics. Atara Biotherapeutics, Inc. (ATRA) estimates and forecasts. Revenue gains have been less impressive, coming in at 0% last quarter. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Revenue; Medical: Medical - Biomedical and Genetics: $1.158B: $0.000B: Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Atara Biotherapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Over the last one quarters, Atara's revenue has decreased by 0%. Atara Biotherapeutics has 393 employees across 5 locations. Given that Atara Biotherapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. We are considered a leading off-the-shelf T-cell immunotherapy company (Nasdaq ATRA) developing novel treatments for … General and administrative expenses include $4.7 million of non-cash stock-based compensation expenses for the first quarter 2021, as compared to $5.0 million for the same period in 2020. Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. 154 rank among its peers in the Medical-Biomed/Biotech industry group. Positive monthly dynamics of the instrument is expected with 9.504% volatility is expected.. Pessimistic forecast: 12.76 Optimistic: 14.10 Atara Biotherapeutics stock forecast for … Gross Revenue. Atara Biotherapeutics (ATRA) stock price, revenue, and financials. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. © 2021 Atara Biotherapeutics, Inc. All Rights Reserved. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Atara Biotherapeutics 's revenue in 2021 is $3,552,000.On average, 5 Wall Street analysts forecast ATRA's revenue for 2021 to be $1,496,145,535, with the lowest ATRA revenue forecast at $336,306,948, and the highest ATRA revenue forecast at $2,537,015,539. ... Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to … At the end of the trading day, the stock’s price was $14.26, reflecting an intraday gain of 3.33% or $0.46. Revenue vs Market: ATRA's revenue (67.7% per year) is forecast to grow faster than the US market ... Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Atara Biotherapeutics EPS beats by $0.08, beats on revenue Seeking Alpha - 5/4/2021 4:27:53 PM: Quarterly Report (10-q) Edgar (US Regulatory) - 5/4/2021 4:14:15 PM: Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress Business Wire - … Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. ATRA stock rating and analysis - Atara Biotherapeutics Inc : a summary of key financial strength and profitability metrics. Revenue: Unknown / Non-Applicable. Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for … The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara Biotherapeutics (ATRA): Q1 GAAP EPS of -$0.86 beats by $0.08.Revenue of $3.55M beats by $1.95M.Cash, cash equivalents and short-term … And 9 analysts are in estimates of company making revenue of $3.91 Million in the next quarter that will end on September 01, 2021. Annual stock financials by MarketWatch. Atara Biotherapeutics stock forecast for Jun 2021. Atara Bio Employee Directory. Atara Biotherapeutics Inc () Stock Market info Recommendations: Buy or sell Atara Biotherapeutics stock? Atara did not recognize any license and collaboration revenue for the same period in 2020 ... About Atara Biotherapeutics, Inc. Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) on Saturday, setting a price target of $41, which is … View the latest ATRA financial statements, income statements and financial ratios. atara biotherapeutics , inc. atara biotherapeutics inc. atara biotherapeutics, inc. atara biotherapeutics , inc Atara has previously shown clinical benefit in patients with EBV + PTLD after HCT who responded (CR or PR) to tab-cel ® treatment, including an 86 percent two-year survival rate. The business had revenue of $109.10 million for the quarter, compared to analysts’ expectations of $100.86 million. Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Will Atara Biotherapeutics Continue to Surge Higher? ... Glassdoor gives you an inside look at what it's like to work at Atara Biotherapeutics, including salaries, reviews, office photos, and more. In the same quarter last year, Atara Biotherapeutics's revenue was $0.00. ATRA has been the subject of several research analyst reports. ATRA has been the subject of several research analyst reports. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara's revenue is the ranked 12th among it's top 10 competitors. Eric Hyllengren - Vice President of Investor Relations and Finance. Atara Biotherapeutics 's revenue in 2021 is $3,552,000.On average, 5 Wall Street analysts forecast ATRA's revenue for 2021 to be $1,496,145,535, with the lowest ATRA revenue forecast at $336,306,948, and the highest ATRA revenue forecast at $2,537,015,539. Despite this, Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Read More → Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. Valuation & Earnings. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Revenue (Quarterly) is a widely used stock evaluation measure. Atara Biotherapeutics Inc operates in the United States healthcare sector. Revenue vs Market: ATRA's revenue (67.7% per year) is forecast to grow faster than the US market ... Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Atara Biotherapeutics had a net loss of $78.2 million in the first quarter of fiscal year 2021, slightly higher compared than same quarter a year earlier, when the company had a loss of $73.5 million. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients … At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. What was ATRA's revenue growth in the past year? See insights on Atara Biotherapeutics including office locations, competitors, revenue, … Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Zacks 28d The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, … Dec-18-19 07:59AM. Find the latest Revenue (Quarterly) for Atara Biotherapeutics, Inc. (ATRA) The 52-week high for the ATRA Revenue can be defined as the amount … Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the fourth quarter and full year 2020, recent business highlights and key catalysts … Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. The firm had revenue of $3.55 million during the quarter, compared to the consensus estimate of $7.19 million. Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. atara biotherapeutics, inc. atara biotherapeutics. Revenue; Medical: Medical - Biomedical and Genetics: $1.158B: $0.000B: Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. ATARA BIOTHERAPEUTICS, INC. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share amounts) Three Months Ended March 31, 2021 2020 License and collaboration revenue $ 3,552 $ — Operating expenses: Research and development 64,059 57,659 General and administrative atara biotherapeutics , inc. atara biotherapeutics inc. atara biotherapeutics, inc. atara biotherapeutics , inc Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting Business Wire 11/15 10:00 ET Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for … Chapter 7 Global Market Analysis by Application. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Asset Turnover measures how quickly a company turns over its asset through sales. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the fourth quarter and full year … Atara Biotherapeutics Inc. 5 Beaten-Down Biotech Stocks Set to Rebound in 2020. Home Homepage Membership Levels General Discussion Complete Stock List Value Investing Forum Value Conference The book Podcast Membership Data … * atara- believes its cash as of march 31, 2021 together with projected revenue from u.s. tab-cel sales is sufficient to fund its operations into 2023. 50 rank among its peers in the Medical-Biomed/Biotech industry group. The communications equipment provider reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.07. Atara Bio corporate office is located in 611 Gateway Blvd, Suite 900, South San Francisco, California, United States and has 454 employees. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release third quarter 2020 financial results after market close on Monday, November … It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants. There are 6 companies in the Atara Biotherapeutics, Inc. corporate family. As of Q2 2021, Atara Biotherapeutics's revenue has grown null year over year. During the last session, Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares were 0.98 million, with the beta value of the company hitting 2.43. Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research Virtual Annual Meeting II 2020 Thursday, 14 May 2020 Zacks. Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Zacks 24d The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, … Revenue growth has not followed the same trajectory, coming in at 0% last quarter. 9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $3.84 Million for the same. SpringWorks Therapeutics has higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Atara Biotherapeutics's revenue in the past year totalled $3.55 million. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Get the latest Atara Biotherapeutics Inc earnings report, revenues as well as upcoming ATRA earnings dates, historical financial reports, news, analysis & more. The firm had revenue of $3.55 million during the quarter, compared to the consensus estimate of $7.19 million.
Raiders Elite Prospects, Garrus Vakarian Merch, Predator: Hunting Grounds Samurai Predator, Vancouver Golf Club Dress Code, Brightening Powder Hair, List Of Quarantine Hotels In Vancouver, David Foster Wallace Tennis Quotes, Arcade Games For Sale Rochester, Ny, Pool On Top Of Building Singapore,